![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Abbott |
---|---|
Information provided by: | Abbott |
ClinicalTrials.gov Identifier: | NCT00640185 |
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
Condition | Intervention | Phase |
---|---|---|
Attention-Deficit/Hyperactivity Disorder |
Drug: ABT-089 Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Parallel Assignment, Safety/Efficacy Study |
Enrollment: | 150 |
Study Start Date: | April 2008 |
Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Placebo Comparator |
Drug: ABT-089
Subjects will take up to two 40 mg tablets once daily for 8 weeks.
Drug: Placebo
Subjects will take one or two placebos once daily for the duration of the study.
|
2: Experimental |
Drug: ABT-089
Subjects will take up to two 40 mg tablets once daily for 8 weeks.
Drug: Placebo
Subjects will take one or two placebos once daily for the duration of the study.
|
3: Experimental |
Drug: ABT-089
Subjects will take up to two 40 mg tablets once daily for 8 weeks.
Drug: Placebo
Subjects will take one or two placebos once daily for the duration of the study.
|
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Lafayette, California, United States, 94549 | |
United States, Florida | |
Orlando, Florida, United States, 32806 | |
Jacksonville, Florida, United States, 32216 | |
United States, Kansas | |
Overland Park, Kansas, United States, 66212 | |
United States, Michigan | |
Farmington Hills, Michigan, United States, 48336 | |
Troy, Michigan, United States, 48085 | |
United States, Oregon | |
Eugene, Oregon, United States, 97401 | |
Portland, Oregon, United States, 97210 | |
United States, Tennessee | |
Memphis, Tennessee, United States, 38119 | |
United States, Virginia | |
Virginia Beach, Virginia, United States, 23452 | |
United States, Washington | |
Bellevue, Washington, United States, 98004 | |
Seattle, Washington, United States, 98104 |
Study Director: | Earle Bain, M.D. | Abbott |
Responsible Party: | Abbott ( Earle Bain, M.D. ) |
Study ID Numbers: | M10-346 |
Study First Received: | March 18, 2008 |
Last Updated: | August 29, 2008 |
ClinicalTrials.gov Identifier: | NCT00640185 |
Health Authority: | United States: Food and Drug Administration |
Signs and Symptoms Attention Deficit Disorder with Hyperactivity Mental Disorders Mental Disorders Diagnosed in Childhood |
Neurologic Manifestations Attention Deficit and Disruptive Behavior Disorders Hyperkinesis Dyskinesias |
Pathologic Processes Disease Nervous System Diseases |